Loading
institutionsInstitution
National Cancer Center Hospital East
National Cancer Center Hospital East in Kashiwa is one of the world's most productive trial sites for gastrointestinal, thoracic and head and neck cancer; it runs the SCRUM-Japan genomic screening platform, a large phase 1 unit and one of Japan's first hospital-based proton facilities.
Also called: NCCHE国立がん研究センター東病院
Overview
NCC Hospital East opened in 1992 in Kashiwa as the second hospital of the National Cancer Center and has become one of the most productive trial sites in the world for gastrointestinal, thoracic and head and neck cancer. It hosts the Exploratory Oncology Research and Clinical Trial Center (EPOC), a large phase 1 unit, one of Japan's first hospital-based proton therapy facilities, and the SCRUM-Japan nationwide genomic screening platform (GI-SCREEN, LC-SCRN, MONSTAR-SCREEN, CIRCULATE-Japan) led by Takayuki Yoshino. Kohei Shitara and Toshihiko Doi have led pivotal gastric and oesophageal cancer trials of trastuzumab deruxtecan, zolbetuximab and nivolumab, and Koichi Goto's thoracic group has led ALK, ROS1 and RET programmes. The campus includes the National Cancer Center's photoimmunotherapy and surgical innovation groups.
Location
Kashiwa, Chiba, JP
Type
cancer center
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#59 · 48 points (0 Newsweek + 0 NCI + 48 from 24 linked objects) · ranking
- SCRUM-Japan and CIRCULATE-Japan
- Phase 1 (EPOC)
- Gastric and oesophageal cancer trials
- Proton therapy
- Photoimmunotherapy
Toshihiko Doi
Director, Department of Experimental Therapeutics, National Cancer Center Hospital East
Phase 1 trialsDrug developmentGastrointestinal oncology
Led the first-in-human study of trastuzumab deruxtecan and runs one of Asia's most productive phase 1 units.
Takayuki Yoshino
Chief, Department of Gastroenterology and GI Oncology, National Cancer Center Hospital East; President, Japanese Society of Medical Oncology
Colorectal cancerctDNA and molecular residual diseasePrecision oncology
Leads CIRCULATE-Japan, the largest ctDNA-guided adjuvant programme in colorectal cancer, and the PARADIGM and SCRUM-Japan GI efforts.
Kohei Shitara
Chief, Department of Gastrointestinal Oncology, National Cancer Center Hospital East
Gastric cancerHER2 and Claudin 18.2Immunotherapy
Principal investigator of SPOTLIGHT and DESTINY-Gastric01, two trials that created new drug classes for stomach cancer.
Koichi Goto
Chief, Department of Thoracic Oncology, National Cancer Center Hospital East
Lung cancerRare oncogenic driversGenomic screening
Leads thoracic oncology at NCC East and the LC-SCRUM-Japan network that connects rare-driver lung cancer patients to trials.
Similar pages
- InstitutionKyushu University Hospital
Shares Japan Clinical Oncology Group (JCOG), National Cancer Center Hospital, RET, Comprehensive genomic profiling.
- InstitutionAichi Cancer Center
Shares Japan Clinical Oncology Group (JCOG), ALK, Comprehensive genomic profiling, Oesophageal cancer.
- InstitutionShizuoka Cancer Center
Shares Japan Clinical Oncology Group (JCOG), Proton therapy machines: cyclotrons, synchrotrons and single-room systems, Proton therapy, Gastric & gastro-oesophageal junction cancer.
- PersonHaruhiko Fukuda
Shares Japan Clinical Oncology Group (JCOG), National Cancer Center Hospital, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer.
- Key paperClinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer
Shares RET, ALK, Circulating tumour DNA (ctDNA), HER2.
- Key paperNILE: clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer
Shares RET, ALK, Circulating tumour DNA (ctDNA), HER2.
- CompanyLucence
Shares RET, ALK, Comprehensive genomic profiling, Liquid biopsy (ctDNA).
- InstitutionOsaka International Cancer Institute
Shares Japan Clinical Oncology Group (JCOG), Comprehensive genomic profiling, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer.
cancers
fronts
technologies
targets
drugs
ApprovedMonoclonal antibody (anti-PD-1)
Nivolumab · Opdivo / Opdivo Qvantig (SC)
ApprovedADC
Trastuzumab deruxtecan · Enhertu